New possibilities in chemotherapy for colorectal cancer

Annals of Oncology

Volumn 10, Issue SUPPL. 6, 1999, Pages

  Bekradda, M ^a   Cvitkovic, Esteban ^b  

^a Cvitkovic et Associes Consultants   (France)

^b HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EDRECOLOMAB; FLUOROURACIL; IRINOTECAN; LEVAMISOLE; NOLATREXED; OXALIPLATIN; PEMETREXED; RALTITREXED; UFT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

EID: 0033402988     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_6.S105     Document Type: Conference Paper

References (75)

1. Wagner JS, Adson MA, Van Heerden JA et coll. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199: 502-8.
2. Hugh TJ, Kinsella AR, Poston GJ. Management strategics for colorectal liver metastasis - Part I. Surg Oncol 1997; 6: 19-30.
3. Yang J-L, Yu Y, Markovic B et coll. Overexpression of c-erbB-2 mRNA and for c-neu oncoprotein is a predictor for metastasis from colorectal cancer. Anticancer Res 1997; 17: 1023-6.
4. Cohen AM, Shank B, Friedman MA. Colorectal cancer. In De Vital VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice, ed 3 Philadelphia, JB Lippincott, 1989; 929-77.
5. Dukes CE. The classification of cancer of the rectum. J Pathol Bcteriol 1940; 50: 527-39.
6. Asler WB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954; 139: 846-51.
7. Wolmark N, Fisher B, Wei HS. The prognostic value of the modification of the duke's C class of colorectal cancer: an analysis of the NSABP clinical trials. Ann Surg 1986; 203: 115-22.
8. Willet C, Tepper JE, Cohen A et al. Obstructive and perforative colonie carcinoma: patterns of failure. J Clin Oncol 1985; 3: 379-84.
9. Goslin R, Stech G, Mac Intyre I et al. The use of preoperative plasma CEA levels for the stratification of patients after curative resection of colorectal cancers. Ann Surg 1980; 192: 747-51.
10. LoGerfo P, Herter F. Carcinoembryonic antigen prognosis in patients with colorectal cancer. Ann Surg 1974; 181: 81-4.
11. Moertel CG, O'Fallon JR, Go VLW et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1986; 58: 603-10.
12. Steel G, Ellenberg S, Ramming K et al. CEA monitoring among patients in multiinstitutional adjuvant GI protocols. Ann Surg 1982; 196: 162-9.
13. Wanebo HJ, Rao B, Pinsky CM et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 1978; 299: 448-51.
14. Wolmark N, Fisher B, Wieand S et al. The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. Ann Surg 1984; 199: 375-81.
15. Albe X, Vassilakos P, Helfer-Guarnori K et al. Independent prognostic value of ploidy in colorectal cancer. A prospective study using image cytometry. Cancer 1990; 66: 1168-75.
16. Kokal WA, Gardine RL, Sheibani K et al. Tumor DNA content in resectable, primary colorectal carcinoma. Ann Surg 1989; 209: 188-93.
17. Scott NA, Wieand HS, Moertel CG et al. Colorectal cancer: Dukes' stage, tumor site, preoperative plasma CEA level and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987; 122: 1375-9.
18. Sinicrope F, Hart J, Brasitus T et al. Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse. Cancer 1994; 74: 2908-17.
19. Moertel CG, Loprinzi CL, Witzig TE et al. The dilemma of stage B2 colon cancer. Is adjuvant therapy justified ? (abstract). Proc Am Soc Clin Oncol 1990; 9: 108.
20. Johnston PG, Fisher EF, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome to adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994; 12: 2640-7.
21. Yamaguchi A, Nakagawara G, Kurosaka Y et al. p 53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 1993; 69: 399-402.
22. Auvinen A, Isola J, Visakorpi T et al. Over expression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994; 70: 293-6.
23. Tomoda H, Kareji Y. Immunohistochemical analysis of p53 in colorectal cancer regarding chemicopathological correlation and prognostic significance. J Surg Oncol 1995; 58: 125-8.
24. Lenz HJ, Danenberg KD, Danenberg P et al. p53 status and thymidylate synthase (TS) expression are associated and predict for recurrence in patients with stage II colon cancer (cc) (abstract). Proc Am Soc Clin Oncol 1996; 15: 215.
25. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of colorectal cancer.Why we still don't know? JAMA 1988; 259: 3571-78.
26. IMPACT Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 106: 939-44.
27. Wolmark N, Rochette H, Mamounas EP et al. The relative efficacy of 5-FU and Leucovorin (FU-LV), 5-FU and Levamisole (Fu-Lev), and 5-FU + Leucovorin and Levamisole (Fu-LV-Lev) in patients with duke's B and C carcinoma of the colon: First report of NSABPC-04 (abstract). Proc Am Soc Clin Oncol 1996; 15: 205.
28. Anderson N, Lokieh JJ. Cancer Chemotherapy and infusional scheduling. Oncology 1994; 8: 99-116.
29. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochem Biophys Acta 1996; 1287: 77-102.
30. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996; 42: 858-68.
31. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996; 69: 38-43.
32. Marra G, Boland CR. Hereditary non polyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J. Nat Cancer Inst 1995; 87: 1114-25.
33. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-12.
34. Riethmuller G, Schneider-Gadicke E, Schlimok G et al. Randomised trial of onoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994; 343: 1177-83.
35. Sugarbaker PH, Gianola FJ, Speyer JL et al. Prospective randomised trial of intravenous vs intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Sem Oncol 1985; 12: 101-11.
36. Taylor I, Machin D, Muller M et al. A randomised controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72: 359-63.
37. SAKK - Swiss Group for Clinical Cancer Research. Long term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995; 345: 349-53.
38. Wolmark N, Rockette H, Petrelli N et al. Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02. Proc Am Soc Clin Oncol 1994; 13: 194.
39. Piedbois P, Bruyse M, Gray R et al. Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: 192.
40. Nitti D et al. Final results of phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITTCCG 1983-1987). Eur J Cancer 1997; 33(8): 1209-15.
41. Burke D, Allen-Mersh TG. Colorectal liver metastases. Postgrad Med J 1996; 72: 464-9.
42. VanderMeer TJ, Callery MP, Meyers WC et al. The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra-abdominal metastases from colorectal carcinoma. Hematol Oncol Clin North Am 1997; 11: 759-77.
43. Blumgart L, Fong Y. Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg 1995; 32: 333-421.
44. McAfee MK, Allen MS, Trastek VF et al. Colorectal lung metastasis: results of surgical excision. Ann Thorac Surg 1992; 53: 780-6.
45. Weaver M, Atkinson D, Zetnel R. Hepatic cryosurgery in treating colorectal metastases. Cancer 1995; 76: 210-4.
46. Korpan N. Hepatic cryosurgery for liver metastases. Long-term follow-up. Ann Surg 1997; 225: 193-201.
47. The Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
48. Cvitkovic E. New anticancer agents in current clinical development (abstract). Eight Mediterranean Congress on Chemotherapy - May 1992
49. Haller D. An overview of adjuvant therapy for colorectal cancer. European J Cancer 1995; 31: App.
50. Cassidy J, Kaye S. New drugs in clinical development in Europe. Hematol Oncol Clin North America 1994; 8: 289-303.
51. Giacchetti S, Zidani R, Perpoint B et al. Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA), with or without oxaliplatin (OXA) in previously untreated patients (pts) with metastatic colorectal cancer (MCC) (abstract). Proc Am Soc Clin Oncolg 1997; 17: A 985.
52. O'Connel MJ, Nagorncy DM, Bernath AM et coll. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998; 16 / 2528-33.
53. Bismuth H, Adam R, Levi F et al. Resection of non resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann surg 1996; 224: 509-22.
54. Bleiberg H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Sem Oncol 1996; 23: 42-50.
55. Schmoll HJ. Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents. Eur J Cancer 1996 (suppl 5); 32A / S18-S22.
56. Kemeny N. Current approaches to metastatic colorectal cancer. Semin Oncol 1994 (suppl 7); 21: 67-75.
57. Piedbois P, Bryse M, Rustum Y et al. Meta-analysis of 5-FU and Leucovorin in patients with advanced colorectal cancer (abstract). Ann Oncol 1992 (suppl 5); 3: 205.
58. Advanced colorectal Cancer meta-analysis Project. Modulation of fluorouracil by Leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate J Clin Oncol 1992; 10: 896-903.
59. Cunningham D, Zalcerg J, Smith I et al. Tomudex (ZD 1694): a novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumors Ann Oncol 1996; 7: 179-82.
60. Seitz JF, Cunningham D Rath U et al. Final results and survival data of a large randomised trial of Tomudex in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5-Fu+LV) (abstract). Proc Am Soc Clin Oncol 1996; 15: 201.
61. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer in chemoth Pharmacol 1988; 22: 333-8.
62. Malk STA, Talbot D, Clarke PI et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990; 62: 1023-5.
63. Nogue M, Segui MA, Batiste E et al. Phase II study of oral tegafur (TF) and low-dose oral leucovorin (LV) in advanced colorectal cancer (ACC) (abstract). Proc Am Soc Clin Oncol 1996; 15: 200.
64. Pazdur R, Lassere Y, Rhodes V et al. Phase II trial of uracil and tegafur plus oral Leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296-2300.
65. Saltz LB, Leichman CG, Young CW et al. A fixed-ratio combination of uracil and florafur (UFT) with low-dose leucovorin: an active oral regimen for advanced colorectal cancer. Cancer 1995; 75: 782-5.
66. Findlay M, Van Custem E, Kocha W et coll. A randomised phase II Xeloda, (Capecitabine) in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 227a, (abstract).
67. Becouarn Y, Yehou M, Ducreux M et coll. Oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity toxicity report. Proc Am Soc Clin Oncol 1997; 16: 229a, (abstract 804).
68. de Gramont A, Vignoud J, Tournigand C et coll. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-9.
69. Berthault-Cvitkovic F, Jami A, Ithzaki M et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 2950-8.
70. Levi KA, Zidani R, Vannetzel JM et coll. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin. fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastasis: a randomised multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
71. Levi F, Zidani R, Missel JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. For the International Organisation for Cancer chronotherapy. Lancet 1997; 350: 681-6.
72. Rougier P, Culine S, Bugat R et al. Multicentric phase II study of first line CPT-11 (irinotecan) in advanced colorectal cancer (CRC). Preliminary results (abstract). Proc Am Soc Clin Oncol 1994; 13: 200.
73. Bugat R, Rougier P, Douillard JY et al. Efficacy of irinotecan HCI (CPT-11) in patients with metastatic colorectal cancer after progression while receiving a 5-FU based chemotherapy (abstract) . Proc Am Soc Clin Oncol 1995; 14: 122.
74. Johnston PG, Allegra CJ. Colorectal cancer biology: clinical implications. Sem Oncol 1995; 22: 418-32.
75. O'Connel MJ, Schaid DJ, Ganju V et al. Current status of adjuvant chemotherapy for colorectal cancer: can molecular markers play a role in predicting prognosis? Cancer 1992; 70(suppl): 1732-9.